新闻动态 News
查看更多 >>
-
2025-06-182025年6月12日至13日,2025人工智能与生物医药生态大会(AIBC2025) 在上海成功举办。大会汇聚了国内外学术界与企业界的众多知名专家学者,共同探讨人工智能(AI)技术在生物医药领域的前沿进展与应用实践。望石智慧研发副总裁黄博博士受邀出席,并就 “小分子药物的 AI 设计” 议题发表了主题演讲。 在6月13日下午的演讲中,黄博博士以 《融合实验电子密度的多模态 AI 生成模型辅助小分子药物设计》 为题,深入解析了望石智慧团队在该领域的创新思路与技术优势。他指出,药物研发过程中产生的实验电子密度数据蕴含巨大价值但尚未被充分挖掘。望石团队创新性地应用成熟的量化理论分析这些数据,深度提取其中信息。这一方法不仅能在分子生成过程中辅助标注非共价相互作用(NCI),从而更全面地理解类药分子与靶点口袋的相互作用模式,还能有效提升虚拟筛选的效率。 黄博博士在报告中着重强调了分子生成模型评估体系的重要性。针对行业普遍存在的两大痛点——“不类药分子‘刷分’现象” 和 “...
-
2025-06-132025年6月13日,北京望石智慧科技有限公司(以下简称“望石智慧”)宣布,其独立自主研发的造血祖细胞激酶1(HPK1)抑制剂SWA1211片,在上海市东方医院完成首例患者给药,正式启动针对晚期实体瘤的Ⅰ期临床研究。 SWA1211片于2025年3月同步获得中国国家药品监督管理局(NMPA)和美国食品药品监督管理局(FDA)的临床试验许可。本研究由上海市东方医院郭晔教授与复旦大学附属肿瘤医院王红霞教授共同牵头,旨在评价SWA1211片在晚期实体瘤患者中的安全性、耐受性、药代动力学特征及初步疗效。 有充分的证据表明,抑制HPK1的活性可以激动人体的免疫功能,达到治疗肿瘤的目的。SWA1211是由望石智慧公司研发团队基于该靶点的结构特点,并应用了公司自主开发的人工智能模型,快速、高效地设计开发出的一款高活性、高选择性的口服小分子HPK1抑制剂。临床前研究表明SWA1211具有同类最佳(Best-in-class)的潜质,在多个肿瘤动物模型中单药表现出显著的抗肿瘤效果,并且与PD-1抗体类药物联用展现出更强的协同抗肿瘤疗效。通过与已披...
-
2025-05-16近日,国内领先的AI制药平台研发企业北京望石智慧科技有限公司(以下简称“望石智慧”)与中国领先的创新驱动型制药企业齐鲁制药集团有限公司上海研发中心正式达成合作。此次合作将深度融合望石智慧自主研发的多模态AI 3D分子生成模型的核心技术优势,为齐鲁制药量身打造小分子药物设计的AI平台。凭借齐鲁制药在创新药研发领域的深厚经验,双方将携手加速早期药物发现进程,推动新药开发向高效、精准的方向迈进,助力创新药研发的突破与发展。 制药+AI融合,破解药物分子设计难题 药物早期研发的核心挑战之一在于设计具有高活性、高选择性和可成药性的分子结构。传统方法试错成本高,周期长。基于对传统药物研发模式的深刻反思与AI技术的理解,齐鲁制药于2024年中期正式启动了“齐鲁AI大脑平台项目”,推动齐鲁制药“AI化”。 望石智慧自主研发的多模态AI 3D分子生成大模型能够基于蛋白质空口袋或参考分子片段,快速精准生成与靶点口袋契合的结构新颖、构象合理且与口袋亲和力高的分子/分子骨架,突破传统药物...
-
2025-04-272025年4月27日,望石智慧(StoneWise)宣布,将在2025年美国癌症研究协会(AACR)年会上以壁报的形式,发布其自主研发的SWA1211(靶向HPK1)口服小分子抑制剂项目的最新研究成果。SWA1211已获得中国国家药品监督管理局(NMPA)和美国食品和药物管理局(FDA)批准,拟用于晚期实体瘤治疗。 本届AACR大会将于当地时间2025年4月25日至30日在美国芝加哥举行。 望石智慧将在此次AACR年会上展示的壁报信息如下: Poster Information 01. Topic SWA1211, a next generation HPK1 inhibitor exhibits superior anti tumor efficacy in preclinical studies 02. Location Poster Section 29 03. Session Date and Time April 29, 2025, 2:00 PM ~ 5:00 PM 04. Poster Number 5825 05. Session Title Immunomodulatory Agents and Interventions 联系我们:bd@stonewise.cn 关于AACR 美国癌症研究协会(AACR)年会是全球历史最悠久、规模最大的肿...
-
2025-04-16全球医药研发智能化浪潮下,AI技术正重塑从靶点发现到临床研究的全流程! 百世传媒重磅打造《AI智药:小分子发现与优化全链突破》线上研讨会,百世传媒-百世药学院汇聚腾迈医药、成都先导、圆壹智慧、望石智慧、碳硅智慧、智化科技、沃时科技、亿药科技、北京大学、胜普泽泰等10+家领军企业,打造年度最具实战价值的AI制药盛会!邀请“AI+制药“优质企业专家,带来最前沿的AI制药实战分享! 4月18日,让我们共同开启小分子智能研发新纪元! 会议议程 09:00AI驱动小分子药物发现:从虚拟筛选到智能优化 田川|应用科学部总监 上海腾迈联新生物技术有限公司 09:50 基于分子生成、计算化学与实验化学的苗头化合物发现整合方案 张宏波|副总裁、新药开发技术服务部负责 HitChem 10:30佰仕问问的本地AI模型构建与模型幻觉对抗策略 陈辰|总经理 百世AI 10:50AI驱动的先导化合物发现与优化 李游|测序与生物信息学总监 成都先导药物开发股份有限公司 11:30多目标优...
-
2024-12-252024年12月21日,CMIS 2024第三届中国医药数智峰会在上海万豪虹桥大酒店圆满落幕!北京望石智慧科技有限公司被授予“2024年度医药行业AI智能新药创研先锋奖”,以肯定其以多模态 AI 分子生成大模型为撬点,帮助药物研发企业围绕IP整合数据、认知及工具,建立更快更好的药物研发新范式的努力与成果。望石创始人&CEO周杰龙同时受邀参与本次会议,并就“小分子创新药早期研发的数智化”进行分享,介绍了AI时代下医药行业的变化、望石对于当前小分子药物创新困局的思考、以及通过AI大模型辅助药物研发的可能性。 ✎ 主题演讲分享 CMIS 2024第三届中国医药数智峰会中,望石创始人&CEO周杰龙就“小分子创新药早期研发的数智化”这一话题进行了分享。从小分子创新药现状出发,揭示了行业内卷及创新困局的表象下,隐藏的数据、认知及工具无法很好串联从而无法被直接使用并转化为生产力的问题。接着周总详细介绍了望石针对这些问题提出的解决方案: 针对当前小分子创新困难、同质化内卷严重的...
学术进展 Academic Progress
查看更多 >>
-
2023-02-28Li, Y., Yuan, T., Huang, B. et al. Nat Commun 14, 1030 (2023). https://doi.org/10.1038/s41467-023-36766-9 Abstract The sodium channel NaV1.6 is widely expressed in neurons of the central and peripheral nervous systems, which plays a critical role in regulating neuronal excitability. Dysfunction of NaV1.6 has been linked to epileptic encephalopathy, intellectual disability and movement disorders. Here we present cryo-EM structures of human NaV1.6/β1/β2 alone and complexed with a guanidinium neurotoxin 4,9-anhydro-tetrodotoxin (4,9-ah-TTX), revealing molecular mechanism of NaV1.6 inhibition by the blocker. The apo-form structure reveals two potential Na+ binding sites within the selectivity filter, suggesting a possible mechanism for Na+ selectivity and conductance. In the 4,9-ah-TTX bound structure, 4,9-ah-TTX bin...
-
2022-10-09Cell. October 04, 2022 DOI:https://doi.org/10.1016/j.cell.2022.09.037 Liming Yan, Yucen Huang, Ji Ge, Zhenyu Liu, Pengchi Lu, Bo Huang, Shan Gao, Junbo Wang, Liping Tan, Sihan Ye, Fengxi Yu, Weiqi Lan, Shiya Xu, Feng Zhou, Lei Shi, Luke W. Guddat, Yan Gao, Zihe Rao, Zhiyong Lou Summary Decoration of cap on viral RNA plays essential roles in SARS-CoV-2 proliferation. Here we report a mechanism for SARS-CoV-2 RNA capping and document structural details at atomic resolution. The NiRAN domain in polymerase catalyzes the covalent link of RNA 5’ end to the first residue of nsp9 (termed as RNAylation), thus being an intermediate to form cap core (GpppA) with GTP catalyzed again by NiRAN. We also reveal that triphosphorylated nucleotide analogue inhibitors can be bonded to nsp9 and fi...
-
2022-09-15Yibo Li, Jianxing Hu, Yanxing Wang, Jielong Zhou, Liangren Zhang, and Zhenming Liu J Chem Inf Model 2020 Jan 27;60(1):77-91. doi: 10.1021/acs.jcim.9b00727. Epub 2019 Dec 20. Abstract The ultimate goal of drug design is to find novel compounds with desirable pharmacological properties. Designing molecules retaining particular scaffolds as their core structures is an efficient way to obtain potential drug candidates. We propose a scaffold-based molecular generative model for drug discovery, which performs molecule generation based on a wide spectrum of scaffold definitions, including Bemis-Murcko scaffolds, cyclic skeletons, and scaffolds with specifications on side-chain properties. The model can generalize the learned chemical rules of adding atoms and bonds to a given scaffold. The generated compounds were evaluated by molecular docking in DRD2 targets, and...
-
2022-09-15Liming Zhao, Mengchen Pu, Huting Wang, Xiangyu Ma, and Yingsheng J. Zhang J Chem Inf Model. 2022 Sep 7. doi: 10.1021/acs.jcim.2c00616. Abstract In recent years, machine learning (ML) models have been found to quickly predict various molecular properties with accuracy comparable to high-level quantum chemistry methods. One such example is the calculation of electrostatic potential (ESP). Different ESP prediction ML models were proposed to generate surface molecular charge distribution. Electrostatic complementarity (EC) can apply ESP data to quantify the complementarity between a ligand and its binding pocket, leading to the potential to increase the efficiency of drug design. However, there is not much research discussing EC score functions and their applicability domain. We propose a new EC score function modified from the one originally develop...
-
2022-09-15Sci Rep. 2022 Sep 6;12(1):15100. doi: 10.1038/s41598-022-19363-6. Lvwei Wang, Rong Bai, Xiaoxuan Shi, Wei Zhang, Yinuo Cui, Xiaoman Wang, Cheng Wang, Haoyu Chang, Yingsheng Zhang, Jielong Zhou, Wei Peng, Wenbiao Zhou & Bo Huang Abstract We report for the first time the use of experimental electron density (ED) as training data for the generation of drug-like three-dimensional molecules based on the structure of a target protein pocket. Similar to a structural biologist building molecules based on their ED, our model functions with two main components: a generative adversarial network (GAN) to generate the ligand ED in the input pocket and an ED interpretation module for molecule generation. The model was tested on three targets: a kinase (hematopoietic progenitor kinase 1), protease (SARS-CoV-2 main protease), and nuclear receptor (vi...
-
2022-06-06Jiangtao Zhang, Yiqiang Shi, Junping Fan, Huiwen Chen, Zhanyi Xia, Bo Huang, Juquan Jiang, Jianke Gong, Zhuo Huang, Daohua Jiang Abstract: Voltage-gated sodium (NaV) channels initiate action potentials. Fast inactivation of NaV channels, mediated by an Ile-Phe-Met motif, is crucial for preventing hyperexcitability and regulating firing frequency. Here we present cryo-electron microscopy structure of NaVEh from the coccolithophore Emiliania huxleyi, which reveals an unexpected molecular gating mechanism for NaV channel fast inactivation independent of the Ile-Phe-Met motif. An N-terminal helix of NaVEh plugs into the open activation gate and blocks it. The binding pose of the helix is stabilized by multiple electrostatic interactions. Deletion of the helix or mutations blocking the electrostatic interactions completely abolish...



